.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,034,230

« Back to Dashboard

Claims for Patent: 5,034,230

Title: Anti-allergic ophthalmics
Abstract:This invention relates to low irritative ophthalmics containing the compound of the formula or salts thereof which are useful for treatment of anti-allergic eye diseases such as allergic conjunctivitis ##STR1##
Inventor(s): Morita; Takakazu (Toyonaka, JP), Iso; Tadashi (Kawachinagano, JP), Kawashima; Youichi (Kyoto, JP), Hikida; Mitsushi (Takatsuki, JP)
Assignee: Santen Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:07/392,922
Patent Claims: 1. An anti-allergic ophthalmic solution comprising a potassium salt of a compound of the formula (I) ##STR4## in a concentration from 0.01 to 1% and at least one buffer selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid and sodium borate, either alone or in admixture with one or more pharmaceutically acceptable excipients.

2. An anti-allergic ophthalmic solution comprising a potassium salt of a compound of the formula (I) ##STR5## disodium hydrogen phosphate, sodium dihydrogen phosphate and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the potassium salt of the compound of the formula (I), the disodium hydrogen phosphate and the sodium dihydrogen phosphate are 0.01 to 1%, 0.1 to 2% and 0.002 to 1%, respectively.

3. An anti-allergic ophthalmic solution comprising a potassium salt of a compound of the formula (I) ##STR6## disodium hydrogen phosphate, potassium dihydrogen phosphate and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the potassium salt of the compound of the formula (I), the disodium hydrogen phosphate, and the potassium dihydrogen phosphate are 0.01 to 1%, 0.1 to 1% and 0.002 to 0.7%, respectively.

4. An anti-allergic ophthalmic solution comprising a potassium salt of a compound of the formula (I) ##STR7## boric acid, sodium borate and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the potassium salt of the compound of the formula (I), the boric acid and the sodium borate are 0.01 to 1%, 0.3 to 2% and 0.3 to 1%, respectively.

5. An anti-allergic ophthalmic solution comprising a potassium salt of a compound of the formula (I) ##STR8## boric acid, monoethanolamine and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the potassium salt of the compound of the formula (I), the boric acid and the monoethanolamine are 0.01 to 1%, 0.3 to 2% and 0.1 to 1%, respectively.

6. The anti-allergic ophthalmic solution according to claim 1, wherein the solution is in a dosage form and the dosage form comprises sterile aqueous eyedrops.

7. An anti-allergic ophthalmic solution prepared by dissolving a potassium salt of the compound of formula (I) ##STR9## to provide said salt in a concentration from 0.01 to 1%, in sterile water containing disodium hydrogen phosphate, sodium dihydrogen phosphate and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the disodium hydrogen phosphate and the sodium dihydrogen phosphate are 0.1 to 2% and 0.002 to 1%, respectively.

8. An anti-allergic ophthalmic solution prepared by dissolving a potassium salt of the compound of the formula (I) ##STR10## to provide said salt in a concentration from 0.01 to 1%, in sterile water containing disodium hydrogen phosphate, potassium dihydrogen phosphate and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the disodium hydrogen phosphate and the potassium dihydrogen phosphate are 0.1 to 1% and 0.002 to 0.7%, respectively.

9. An anti-allergic ophthalmic solution prepared by dissolving a potassium salt of the compound of the formula (I), ##STR11## to provide salt in a concentration from 0.1 to 1%, in sterile water containing boric acid, sodium borate and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the boric acid and the sodium borate are 0.3 to 2% and 0.3 to 1%, respectively.

10. An anti-allergic ophthalmic solution prepared by dissolving a potassium salt of the compound of the formula (I) ##STR12## to provide said salt in a concentration from 0.01 to 1%, in a sterile water containing boric acid, monoethanolamine and optionally one or more pharmaceutically acceptable excipients, wherein the concentrations of the boric acid and the monoethanolamine are 0.3 to 2% and 0.1 to 1%, respectively.

11. A method of treatment of allergic eye diseases which comprises administering to a patient the anti-allergic ophthalmic solution according to claim 1 in an amount effective to treat an allergic eye disease.

12. The method according to claim 11, wherein the solution is topically administered to the eye of the patient in a dosage form and the dosage form comprises sterile aqueous eye drops.

13. A method of treatment of allergic eye diseases which comprises administering to a patient the anti-allergic ophthalmic solution according to claim 2 in an amount effective to treat an allergic eye disease.

14. A method of treatment of allergic eye diseases which comprises administering to a patient the anti-allergic ophthalmic solution according to claim 3 in an amount effective to treat an allergic eye disease.

15. A method of treatment of allergic eye diseases which comprises administering to a patient the anti-allergic ophthalmic solution according to claim 4 in an amount effective to treat an allergic eye disease.

16. A method of treatment of allergic eye diseases which comprises administering to a patient the anti-allergic ophthalmic solution according to claim 5 in an amount effective to treat an allergic eye disease.

17. The anti-allergic ophthalmic solution according to claim 1, wherein the concentration of the potassium salt of the compound of the formula (I) is about 0.1 to 1%.

18. The anti-allergic ophthalmic solution according to claim 2, wherein the concentration of the potassium salt of the compound of the formula (I) is about 0.1 to 1%.

19. The anti-allergic ophthalmic solution according to claim 3, wherein the concentration of the potassium salt of the compound of the formula (I) is about 0.1 to 1%.

20. The anti-allergic ophthalmic solution according to claim 4, wherein the concentration of the potassium salt of the compound of the formula (I) is about 0.1 to 1%.

21. The anti-allergic ophthalmic solution according to claim 5, wherein the concentration of the potassium salt of the compound of the formula (I) is about 0.1 to 1%.

22. A method of treatment of an allergic eye disease which comprises topically administering to a patient the anti-allergic ophthalmic solution according to claim 17 in an amount effective to treat an allergic eye disease.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc